Global rheumatoid arthritis market was valued at USD 24.46 Billion in 2020 and is expected to register a healthy CAGR through 2021-2026.

Industry Snapshots

• One of the major factors that are driving the growth global rheumatoid arthritis market is the increasing aging population.
• The introduction of medicinal drugs and the favorable reimbursement practices for expensive medical equipment are also fueling the overall market size.
• Additionally, there has been an increase in funding given to academic research organizations and individual researchers, which is anticipated to stimulate industry outlook as well.
• The market is also expected to develop as a result of several programs by international organizations like the WHO and NIH for preventing and treating chronic illnesses like cancer, rheumatoid arthritis, and cardiovascular disease.

Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/4383305/

Segmental Overview

Drug Type	NSAID (non-steroidal anti-inflammatory drugs)
	Corticosteroids
	DMARD'S (Disease-modifying anti-rheumatic drug)
	Others
Treatment Type	Joint fusion
	Joint replacement
	Tendon repair
	Others
Diagnosis Type	CRP
	ESR
Regional Landscape	Americas
	Asia Pacific
	Europe

 

Window to the future

• On the back of the rising rates of rheumatoid arthritis, the DMARDs segment is anticipated to capture a sizable market share in the ensuing years.
• Americas held the largest share in global rheumatoid arthritis market in 2020 and is expected to garner substantial gains, primarily due to its extensive patient base, accessibility to a well-developed infrastructure, growing elderly population, and widespread usage of biopharmaceuticals for treatment.

Explainer

The companies analyzed in the worldwide rheumatoid arthritis report include Sanofi S.A., Merck KGaA, Eli Lilly Company, Bristol-Mayor Squibb, Amgen Inc., F. Hoffman-La Roche Ltd., Cipla Ltd., Johnson & Johnson, Pfizer Inc., Gilead Sciences Inc., and Galapagos NV. 

Concluding Lines

Market research essentially involves providing detailed information of a commercial landscape that could take weeks or months to gather. To that effect, MarketStudyReport offers a study on ‘Global Rheumatoid Arthritis Market (2021 Edition) - Analysis By Drug Type (NSAIDs, DMARDs, Corticosteroids, Others), Treatment, Diagnosis, By Region, By Country: Market Insights and Forecast with Impact of COVID-19 (2021-2026)’, which provides information on the expansion prospects, segmental analysis, geographical reach, and leading players in this industry vertical to ensure high profitability among those looking to invest in this business space.